Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. - Wikidata - wikimedia - TriplyDB

Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.

Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.

http://www.wikidata.org/entity/Q36870858

about

Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci Advances in the management of sepsis and the understanding of key immunologic defects Treatment of Gram-positive infections in critically ill patients Genome-Wide Identification of Antimicrobial Intrinsic Resistance Determinants in Staphylococcus aureus Whole genome sequencing and complete genetic analysis reveals novel pathways to glycopeptide resistance in Staphylococcus aureus Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin.Teicoplanin as an effective alternative to vancomycin for treatment of MRSA infection in Chinese population: a meta-analysis of randomized controlled trials.Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?Characterization of methicillin-resistant Staphylococcus aureus isolates from patients with persistent or recurrent bacteremia.Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes.Comparison of commercial antimicrobial susceptibility test methods for testing of Staphylococcus aureus and Enterococci against vancomycin, daptomycin, and linezolid Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin.Predictors of Adverse Outcomes in Children With Staphylococcus aureus Bacteremia Vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations: study protocol for a phase IIB randomized controlled trial.Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections Ceftaroline fosamil: a brief clinical review.Observation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains.Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs.Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus.The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia.Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus.Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study.Daptomycin therapy for osteomyelitis: a retrospective study.Empiric weight-based vancomycin in intensive care unit patients with methicillin-resistant Staphylococcus aureus bacteremia.Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis Vancomycin revisited - 60 years later High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis.Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study Is vancomycin MIC creep a worldwide phenomenon? Assessment of S. aureus vancomycin MIC in a tertiary university hospital The efficacy and safety of linezolid and glycopeptides in the treatment of Staphylococcus aureus infections Predicting high vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus bloodstream infections Ceftaroline in Combination With Trimethoprim-Sulfamethoxazole for Salvage Therapy of Methicillin-Resistant Staphylococcus aureus Bacteremia and Endocarditis.Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis.Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients?

P2860

Q22305769-BBF73505-F9ED-47C8-B415-8972F374CA8F Q24646677-252B92DD-1029-4938-9B1B-BB281BB62F53 Q26853465-6188D05A-52F6-49CB-B857-AC20C47D139C Q26865386-A0F53E07-982E-4FA9-8819-4299F4519919 Q27015976-1C9DCB3E-68BE-4BFA-84C2-DC7391799763 Q28354064-2733041D-C2FF-4B56-A29D-77D307C7CA3E Q28478770-0C987C3E-2542-4E6C-8955-74F2AA59FAA5 Q28534516-087DEB95-33FA-445A-BF22-CED79D6C829F Q30455758-FC486F62-E261-43A4-92CC-01151B88A78F Q31144203-CBB53F5B-E46A-46F0-9867-68E7EB23AD20 Q33596888-DA58E9BF-F2F0-4762-AD18-A2C6C7321ECF Q33617737-E9593066-563A-4254-9ACE-4AAB7C5E0DFF Q33640218-0A8137CF-DD54-4076-A2C2-3046C1E7151C Q33642100-728F7A3E-0D10-42F7-AA8F-6373B88A6AF4 Q33703519-382AE767-AF1A-4828-996C-DFD35AED1D70 Q33704710-91A309C3-0FDA-4F5D-A091-D2BC533CE6FA Q33806504-F31BF7B4-DF8A-41D5-86FD-49A801919E07 Q33844670-F8EF936C-43BD-4E66-BCD9-7664AD7F183A Q33881584-A6FDED32-A935-428D-90C4-7AEABD69BADF Q33939080-057CE38C-5D98-45A0-AAE0-56A60BC7E6D3 Q33939095-4139A5D8-15F7-405A-9F41-96177F5DD55D Q33997671-0EBE8724-6117-4639-94FB-D5BA818081C6 Q34058222-00F21FBC-7DD8-4512-B0AD-C3821CF0D65A Q34091829-3F2CAE8F-C5A7-42D0-856F-B1AA1A4897A0 Q34108614-E1D57144-4D66-42A7-82D1-6F355B4DDC4F Q34157657-951DF5A3-B3DA-4B4F-BA61-5B4998FECDC5 Q34249501-9895B03C-F6D3-4B9D-BA79-790D0E022423 Q34301398-E0AB102F-9C64-4D44-8974-3C634CE09BAD Q34396004-F2EE7988-56C4-407D-A0D2-8A67378DFB8A Q34405301-F25D357D-37DA-4936-8BC5-1D309683382F Q34433066-2CC29719-9E41-4202-A908-3C1057A3064B Q34454418-C17234D8-ADE8-4086-99AB-B07BE428F372 Q34529205-F27586F5-CE47-45E9-AEF8-912D1FB4EA30 Q34583169-CDCB9534-6F4D-4D31-97C2-5BC9C3080985 Q34591873-502D2CE6-9D49-401A-AF92-8FFC869D5EA2 Q34618696-68FE6149-55B4-4EFF-A25D-169840CA1B95 Q34756833-AF6DF442-7276-407D-A947-58BD3957793E Q34801960-6FF9C146-CE0C-4237-9B6D-9493452E840B Q34926950-3D85CEC3-3246-45F7-9202-5A4CDB8874E9 Q34967980-F672419C-A535-4D54-8F04-9B9E6D6FA237

P2860

Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.

http://www.wikidata.org/entity/Q36870858

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Relationship between vancomyci ...... remia treated with vancomycin.

@en

type

label

Relationship between vancomyci ...... remia treated with vancomycin.

@en

prefLabel

Relationship between vancomyci ...... remia treated with vancomycin.

@en

P1433

Q36870858-47D952ED-598D-419D-8C19-DEA2DE5052AB

P1476

Q36870858-2F10ACF1-65A3-4B28-8484-C620DBB7968B

P2093

Q36870858-319D7C8F-B51A-49D2-B183-E4B73950ED1C

Q36870858-4668D7E7-4C9F-4C40-9C97-1846227A7C1C

Q36870858-5C781A1A-55F2-4C0F-B776-F0BAA180F938

Q36870858-67A86341-41F3-4BFC-A99C-22059FFEF181

Q36870858-D9F1AFA0-4BA6-47BD-BD53-E2109C99D0DB

Q36870858-FDEE93F5-7CB7-418A-8637-F3B038539A37

Q36870858-FDFCA185-9BC3-49D4-88EA-40E891A777CB

P2860

Q36870858-0906B9D9-4151-4425-93EC-C9F7EBC2024D

Q36870858-0DFA116F-55A0-4386-A767-D6CCB17DD379

Q36870858-1FCAFE2F-C99D-41A6-9D1D-20A582B8FD7A

Q36870858-28C954CB-D21E-4F69-AD14-59C94C9F041A

Q36870858-2C82A8B2-8A09-4CE7-AE05-FA74E08316AC

Q36870858-34F9DBA0-CACC-43CD-B993-12E0477390D5

Q36870858-4969B935-689D-4307-9606-108402056A4D

Q36870858-5053D1AB-7BF5-42E3-B1EE-E646EB67B05C

Q36870858-82D7F875-1A06-4089-B125-A534885FC8C9

Q36870858-92905952-67EA-4099-99AA-3A83E32DA10E

P304

Q36870858-4DCE5E7D-0712-4AE8-9E43-472AF07A16CA

P31

Q36870858-E572A3B3-0198-4593-9D96-C63A89302E8D

P356

Q36870858-F8F5B118-0153-42A4-B5AA-55FB29FF32CB

P407

Q36870858-AAB15590-29D3-44CD-90F7-F4BB8E6EEB49

P433

Q36870858-AD07A681-24E4-4885-B372-304EF356D173

P478

Q36870858-EC8EE5A7-652E-43A2-884C-87A1CC848489

P577

Q36870858-D946DC9C-0033-4234-B3E1-4FB0FC788393

P698

Q36870858-014DDA94-2BBD-4F9A-9BAD-606D442351D5

P921

Q36870858-4D3347A9-669B-4572-BB37-30370EFCC520

P932

Q36870858-ED6FC474-3158-41A2-B903-62CFFB5307C5

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Relationship between vancomyci ...... remia treated with vancomycin.

@en

P2093

A Evans

http://www.w3.org/2001/XMLSchema#string

B M Lomaestro

http://www.w3.org/2001/XMLSchema#string

E Graffunder

http://www.w3.org/2001/XMLSchema#string

J Graves

http://www.w3.org/2001/XMLSchema#string

K Stellrecht

http://www.w3.org/2001/XMLSchema#string

M Helmecke

http://www.w3.org/2001/XMLSchema#string

T P Lodise

http://www.w3.org/2001/XMLSchema#string

P2860

APACHE II: a severity of disease classification system

Prediction of creatinine clearance from serum creatinine

Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.

Guidelines for the management of intravascular catheter-related infections.

Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus.

Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy.

The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.

A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients.

P304

3315-3320

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00113-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18591266

http://www.w3.org/2001/XMLSchema#string

P921

methicillin-resistant Staphylococcus aureus

P932

2533486

http://www.w3.org/2001/XMLSchema#string